Physician profile
Thomas G Van Dinter
NPI 1518184365
$4,091.26
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $445 · 2021: $746 · 2022: $791 · 2023: $912 · 2024: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Education: $14.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.11 |
| Education | $14.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,930.21 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $276.72 | 2019-2024 | Entyvio |
| Celgene Corporation | $177.25 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $162.40 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $144.37 | 2021-2023 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.97 | 2019-2024 | Trulance, Xifaxan |
| Aimmune Therapeutics, INC. | $133.90 | 2024 | |
| Ferring Pharmaceuticals INC. | $101.33 | 2019-2024 | Clenpiq, Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.15 | 2023 | Cyltezo |
| Boston Scientific Corporation | $98.46 | 2019 | |
| Nestle Healthcare Nutrition INC. | $80.54 | 2021-2023 | |
| Gilead Sciences, INC. | $75.16 | 2019-2021 | |
| Daiichi Sankyo INC. | $70.72 | 2019-2022 | |
| Janssen Biotech, INC. | $54.53 | 2022-2024 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $53.20 | 2024 | Resmetirom |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.31 | 2023 | Avsola, Amjevita |
| Braintree Laboratories, INC. | $43.55 | 2020-2023 | Suflave |
| Redhill Biopharma INC. | $43.41 | 2021-2022 | |
| Qol Medical, LLC | $38.03 | 2021 | |
| Ironwood Pharmaceuticals, INC | $37.14 | 2021 | |
| Ucb, INC. | $31.25 | 2019 | |
| Medtronic, INC. | $30.52 | 2022 | |
| Fresenius Kabi USA, LLC | $30.09 | 2023 | Idacio |
| Organon LLC | $28.99 | 2021-2023 | Renflexis, Hadlima |
| Vivus LLC | $28.93 | 2023-2024 | Pancreaze, Qsymia |
| Ardelyx, INC. | $28.48 | 2023 | Ibsrela |
| Lilly USA, LLC | $21.96 | 2024 | Omvoh |
| Shire North American Group INC | $21.95 | 2019 | |
| Biofire Diagnostics, LLC | $18.01 | 2020 | |
| Celltrion USA INC. | $14.45 | 2024 | Zymfentra |
| Dynavax Technologies Corporation | $12.20 | 2019 | |
| Allergan, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Van Dinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.